- Aug 31, 2022 Foghorn Therapeutics Announces Change to Board of Directors
- Aug 23, 2022 Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
- Aug 17, 2022 Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
- Aug 09, 2022 Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
- Aug 01, 2022 Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
- May 31, 2022 Foghorn Therapeutics Announces Upcoming Investor Conference Participation
- May 19, 2022 Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
- May 09, 2022 Foghorn Therapeutics Provides First Quarter 2022 Corporate Update
- Apr 13, 2022 Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting
- Apr 01, 2022 Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
Displaying 11 - 20 of 25